<DOC>
	<DOCNO>NCT02609789</DOCNO>
	<brief_summary>The purpose study assess safety tolerability JNJ-55920839 follow single ascend intravenous ( IV ) dose administration healthy participant single subcutaneous dose healthy participant multiple IV dose administration participant mild moderate Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Single Ascending Dose Study Healthy Participants Multiple Dose Study JNJ-55920839 Participants With Mild Moderate Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This Phase 1 , randomize , placebo-controlled , multicenter study JNJ-55920839 . The study consist Screening Period 28 day . The healthy participant 6-day/5-night inpatient period . All Participants receive study agent Day 1 SLE Participants receive additional dos Days 15 , 29 , 43 , 57 , 71 . The total duration participation participant approximately 13 week healthy participant , 22 week participant SLE . All eligible participant randomly assign receive active agent placebo . The study conduct 2 part . In Part 1 , single ascending dos JNJ55920839 placebo administer sequential cohort healthy participant IV infusion subcutaneous injection . In Part 2 , multiple dos JNJ-55920839 placebo administer IV infusion participant SLE . Blood sample collect assessment pharmacokinetic pharmacodynamics parameter part 1 2 , along assessment safety clinical outcome . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Part A ( Healthy Participants ) Participant must willing/able adhere study visit schedule requirement , prohibition , restriction specify protocol Participant must body weight range 50 90 kilogram ( kg ) , inclusive , body mass index ( BMI ) 18 30 kilogram per square meter kg/m^2 , inclusive , screen Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen . The determination evidence active underlying illness physical examination must record Participant 's source document initial investigator Participant must healthy basis clinical laboratory test perform screen Before randomization , woman must : Not childbearing potential : postmenopausal ( &gt; 45 year age amenorrhea least 12 month age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 international unit per liter ( IU/L ) mIU/mL ) ; permanently sterilize ( e.g. , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) ; otherwise incapable pregnancy A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 4 month ( &gt; = 5 halflives ) receive last dose study agent A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control e.g. , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 4 month ( &gt; =5 halflives ) receive last dose study agent Part B ( Participants Systemic Lupus Erythematosus ) Participant must willing/able adhere study visit schedule requirement , prohibition , restriction specify protocol Participant must body weight range 40 100 kg , inclusive , BMI 18 30 kilogram per square meter ( kg/m^2 ) , inclusive , screen Must meet Systemic Lupus International Collaborating Clinics ( SLICC ) criteria diagnosis lupus Part A ( Healthy Participants ) Coexisting medical condition past medical history : Participant currently history clinically significant medical illness medical disorder investigator considers significant exclude participant , include ( limited ) , neuromuscular disorder , hematological disease , immune deficiency state , respiratory disease , cardiovascular disease ( include poor peripheral venous access ) , hepatic gastrointestinal ( GI ) disease , neurological psychiatric disease , ophthalmological disorder , neoplastic disease , renal urinary tract disease , dermatological disease . Careful consideration give whether participant severe , progressive , uncontrolled hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic/ cerebral , psychiatric disease , current sign symptom thereof Participant condition might confound assessment include major surgery , substance abuse acute illness Participant woman childbearing potential woman pregnant , breastfeeding , plan become pregnant enrolled study within 4 month ( &gt; =5 halflives ) last dose study agent Part B ( Systemic Lupus Erythematosus [ SLE ] ) Participant history suspect occurrence druginduced SLE Participant active Central nervous system ( CNS ) lupus history severe CNS lupus include limited seizure , psychosis , transverse myelitis , CNS vasculitis optic neuritis Participant currently history clinically significant medical illness medical disorder investigator considers significant exclude Participant , include ( limited ) , neuromuscular disorder , hematological disease , immune deficiency state , respiratory disease , cardiovascular disease ( include poor peripheral venous access ) , hepatic gastrointestinal ( GI ) disease , neurological psychiatric disease , ophthalmological disorder , neoplastic disease , renal urinary tract disease , dermatological disease . Careful consideration give whether Participant severe , progressive , uncontrolled hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic/ cerebral , psychiatric disease , current sign symptom thereof Participant major surgery , ( e.g. , require general anesthesia ) within 4 month screen , fully recover surgery , surgery plan within 4 week prior study agent administration time Participant expect participate study , within 4 month ( &gt; =5 halflives ) last dose study agent administration Participant laboratory finding biopsy result consistent severe lupus nephritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>JNJ-55920839</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>CNTO 6358</keyword>
</DOC>